A review of the data on risk of infection, malignancy, and death associated with therapies for IBD.
James D. Lewis, MD, MSCE
Advertisement
Articles by James D. Lewis, MD, MSCE
Advertisement
Latest Updated Articles
- Biologic Safety in IBD: Malignancy and Infection
October 20th 2010
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5